Indian drugmakers primarily produce generics, or copycat versions, and in order to enter the market, they either have to wait for patents to expire or challenge the innovator’s rights.
​Indian drugmakers primarily produce generics, or copycat versions, and in order to enter the market, they either have to wait for patents to expire or challenge the innovator’s rights. by Soban News (international And National News)
